Grapevine

Fidson’s drug manufacturing pact with Chinese firms raises hope for Nigeria’s HIV patients

Drug maker Fidson Healthcare is betting that its new partnership with a trio of Chinese organisations will drive the quest to tame the spread of HIV/AIDS cases in Nigeria and the rest of the African continent.

The partnership is expected to help Nigeria, which leads the West and Central African sub-region in terms of HIV/AIDS cases, find remedy for its teeming patients.

“We eagerly look forward to this collaboration and believe that the comprehensive strengths of all parties will inject new vitality into the healthcare delivery sector in Africa,” CEO Fidelis Ayebae said in a statement on Wednesday.

In addition, the deal will address “the medical needs of over 1.9 million HIV-infected individuals in Nigeria, a focus of Aidea PharAidea.”

The joint venture partners with Fidson include Jiangsu Idea Pharma, Nanjing PharmaBlock and the China-Africa Development Fund.